There are desirable and undesirable effects of high-deductible health plans, and the use of value-based insurance design may mitigate adverse effects of these plans, explained Niteesh Choudhry, MD, PhD, associate professor of medicine at Harvard Medical School.
There are desirable and undesirable effects of high-deductible health plans, and the use of value-based insurance design may mitigate adverse effects of these plans, explained Niteesh Choudhry, MD, PhD, associate professor of medicine at Harvard Medical School.
Transcript (slightly modified)
What do we know so far about how high-deductible health plans affect adherence?
So there’s an evolving literature now about high-deductible health plans (HDHPs) and medications. And so the literature is a little bit mixed, but what we know so far is that HDHPs tend to make people shift away from expensive medications to lower-cost medications like generics, which in many cases may be perfectly appropriate. And so that is a very desirable result of a HDHP.
Emerging data from our group is suggesting that the introduction of a HDHP or somebody transitioning to a HDHP also leads to the reduction in the use of essential medications—medications for heart disease, and diabetes, and high cholesterol—and those would be considered adverse effects or things that we would not want HDHPs to do. The magnitude of the effects is actually relatively large, 4-6 percentage points, and those normally translate, especially for evidence-based medications, to clinically meaningful impacts.
So that’s an example of the role of where value-based insurance design for these medications may fit with a HDHP as a method to mitigate the adverse effects of the plans themselves.
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More